• Customer Login
  • Search
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
    • Zimeta™ (dipyrone injection)
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Pipeline
  • Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • epoCat™ (feline recombinant erythropoietin)
      • Zimeta™ (dipyrone)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu

Best Medicines for Our Best Friends

KindredBio develops innovative medicines for cats, dogs, and horses.

Innovation

KindredBio is a leading veterinary biotech company in the world,

with extensive pipeline of drugs and recombinant protein therapeutics.

Our Mission

To bring the best science and medicine to our animal companions. 

PURSUE PROVEN SCIENCE AND EFFECTIVE SOLUTIONS

We identify drugs and biologics that work in humans, and we develop veterinary versions for cats, dogs, and horses. By adapting the research and development from existing human products, we both increase the chance of success and decrease costs and timelines.

FOCUS ON EFFICIENCY

We have a world-class team, experienced in both human and veterinary therapeutic development and have selected best practices from both fields.  Our methodical approach is resulting in groundbreaking veterinary drugs and biologics for an average of approximately $5 million to $8 million in only 3 to 5 years.

CREATE VALUE FOR ALL STAKEHOLDERS

We don’t compromise between the best veterinary treatments and return on investment.  By efficiently adapting existing human treatments, we create value for everyone: cats, dogs, and horses, owners, veterinarians, and our employees and shareholders.

2019 Proxy Statement and 10-K now available

  • Form 10-K
  • KindredBio Bylaws
  • 2019 Proxy Statement

News

  • Kindred Biosciences Receives FDA Approval of Zimeta™ (dipyrone injection) for the Control of Pyrexia in HorsesNovember 25, 2019 - 4:07 pm
  • Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:08 pm
  • Kindred Biosciences Announces Third Quarter 2019 Financial ResultsNovember 12, 2019 - 4:04 pm

Events

  • Event: Kindred Biosciences to Present at Stifel Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Participate at Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Announce Third Quarter 2019 Financial ResultsOctober 28, 2019 - 8:35 am
$7.60 Stock is Down -0.08 (-1.04%)
KIN (Common Stock)
Previous Close Volume
$7.68 54,343
Intraday High Intraday Low
$7.70 $7.56
52 Week High 52 Week Low
$12.99 $5.96
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

© Copyright 2012-2019 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
Scroll to top